Retinal Physician

💉 New insights into steroid strategies for diabetic macular edema. Ashish Sharma & Baruch D. Kuppermann discuss how corticosteroids are being incorporated into DME management, from patient selection to dosing and safety considerations 👁️ ow.ly/v7YA50Z08V9 #Retina

👁️‍🗨️ At #ARVO2026, NEI Director Michael Chiang, MD, highlighted new opportunities for vision research through AI, precision medicine, collaboration & data sharing 🚀 Ophthalmology researchers are being encouraged to help shape the future of innovation: retinalphysician.com/issues/2026/ma…

At #RetinaWorldCongress, Sunir J. Garg, MD, FACS, shared practical strategies to help retina specialists reduce neck, back, wrist, and shoulder strain through better posture, workspace setup, and OR positioning. Read more 👇 ow.ly/cUbk50Z2zlc #Ophthalmology #Retina

👁️ New research from Abraham Olvera-Barrios, MD, PhD, and Cathy Egan, FRANZCO, explores how automated retinal imaging systems could improve detection, reduce workload, and expand access to care worldwide 🌍 Read more: ow.ly/v4gP50Z08Bc #Ophthalmology

Could GLP-1 therapies impact retinal disease risk? 👀 New evidence reviewed at Retina World Congress suggests some retinal safety signals may be real, especially in patients with preexisting diabetic retinopathy. Read more: ow.ly/5A2z50Z1vcj #Ophthalmology #GLP1 #Retina

🚨 #ARVO2026: Phase 2 Alluvium data showed IL-6 inhibitor vamikibart improved visual acuity and retinal anatomy in treatment-naïve DME patients. The findings support further exploration of combining anti–IL-6 and anti-VEGF approaches in #retina care. ow.ly/LxAs50Z1HB1

🚨 FDA updates from #RetinaWorldCongress 2026 could reshape retina drug development. William M. Boyd discussed: 👁️ AI-assisted FDA review 👁️ Real-time clinical trial monitoring 👁️ Faster approval pathways 👁️ Rare retinal disease initiatives Read more: ow.ly/CSYr50Z1uOY

Could retinal biomarkers help personalize DME treatment? 👁️✨ This article explores how OCT and OCTA imaging may help predict treatment response, guide therapy selection, and improve outcomes in diabetic macular edema. Read more: ow.ly/Z6SK50YYVI9 #Retina

How do we move ophthalmic AI from concept to clinical reality? 👁️ At Focus A-Eye Summit, clinicians & industry leaders came together to discuss barriers to AI adoption and what it will take to move from innovation to practical clinical use. Read more: ow.ly/FxUg50YYVmW

at #ARVO2026, Baruch D. Kuppermann, MD, PhD, presented findings from the DME AWARE Delphi Study highlighting key unmet needs in DME management, including earlier intervention, noninvasive therapies, and improved treatment adherence. 👉 Read more: ow.ly/5t3b50YVXBy

Could AI help reduce screen failures in geographic atrophy clinical trials? Data presented at #ARVO2026 showed a clinic-based AI tool reduced screen failure rates and demonstrated close agreement with manual measurements during GA trial prescreening. 👉 ow.ly/rCHF50YVXkz

How quickly does faricimab reduce retinal fluid in real-world DME patients? At #ARVO2026, Robert P. Finger presented 6 month VOYAGER data showing meaningful reductions in intraretinal and subretinal fluid, with changes detectable as early as month 1. 👉 ow.ly/wrqX50YVXvu

How is @NatEyeInstitute supporting innovation amid funding pressure? At #ARVO2026, NEI Director Michael F. Chiang, MD, discussed funding stability, AI, and why #ophthalmology continues to play an outsized role in broader medical innovation. 👉 Read more: ow.ly/QyKS50YVX5p

A global retina agenda, international faculty, clinical research, surgical education, and panel discussions from across the field. Baruch D. Kuppermann, MD, PhD, previews what attendees can expect from the upcoming #RWC2026 meeting. 🎥 ow.ly/Q4S350YW0ZQ

📢 New issue out now! 👁️ Our latest issue explores what’s shaping clinical practice today, from DME biomarkers and AI screening to evolving DR management and practical steroid strategies you can apply in clinic + more! 👉 Download ow.ly/Z78s50YVAAn #RetinalPhysician

Christopher D. Riemann, MD is challenging how we approach DME. NEW DAY trial insights suggest fewer injections with similar outcomes using fluocinolone acetonide. 👉 Read his perspective: ow.ly/kChh50YR3lA #Ophthalmology #Retina

“Payers don’t reimburse based on what happened. They reimburse based on why it was necessary.” Elizabeth Cifers breaks down how documentation gaps drive denials, delays, and audit risk in retina practices. Read more: ow.ly/2Xgl50YNwen #Retina #MedicalCoding #Ophthalmology

Is uveitis really as “scary” as trainees think? New insights from US uveitis specialists challenge common myths around surgery, compensation, and complexity. Featuring Gonzales, Shantha, Arepalli, Tsui, and Liberman. Read more: ow.ly/k0y450YIKX1 #Uveitis #Ophthalmology

What is next for nAMD? Naveen Karthik, MD, and Sharon Fekrat, MD, FASRS, review emerging biologics and gene therapies aiming to extend durability and reduce treatment burden. Read more: ow.ly/sFma50YGpfO #Retina #nAMD